PT932597E - Utilizacao de amidas do acido gama-hidroxibutirico no tratamento da toxicodependencia e particularmente do alcoolismo - Google Patents
Utilizacao de amidas do acido gama-hidroxibutirico no tratamento da toxicodependencia e particularmente do alcoolismoInfo
- Publication number
- PT932597E PT932597E PT97941921T PT97941921T PT932597E PT 932597 E PT932597 E PT 932597E PT 97941921 T PT97941921 T PT 97941921T PT 97941921 T PT97941921 T PT 97941921T PT 932597 E PT932597 E PT 932597E
- Authority
- PT
- Portugal
- Prior art keywords
- alkyl
- treatment
- halo
- double
- optionally substituted
- Prior art date
Links
- 208000007848 Alcoholism Diseases 0.000 title 1
- 239000002253 acid Substances 0.000 title 1
- 201000007930 alcohol dependence Diseases 0.000 title 1
- 125000000217 alkyl group Chemical group 0.000 abstract 6
- 125000005843 halogen group Chemical group 0.000 abstract 3
- 125000003118 aryl group Chemical group 0.000 abstract 2
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 150000001408 amides Chemical class 0.000 abstract 1
- 125000004429 atom Chemical group 0.000 abstract 1
- 125000002837 carbocyclic group Chemical group 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 206010013663 drug dependence Diseases 0.000 abstract 1
- 125000000623 heterocyclic group Chemical group 0.000 abstract 1
- 125000002950 monocyclic group Chemical group 0.000 abstract 1
- 208000011117 substance-related disease Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/36—Radicals substituted by singly-bound nitrogen atoms
- C07D213/40—Acylated substituent nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Addiction (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychiatry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pyridine Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT96MI001732A IT1283782B1 (it) | 1996-08-09 | 1996-08-09 | Uso di ammidi dell'acido gamma-idrossibutirrico nel trattamento di tossicodipendenze,ed in particolare sell'alcolismo |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT932597E true PT932597E (pt) | 2002-09-30 |
Family
ID=11374795
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT97941921T PT932597E (pt) | 1996-08-09 | 1997-08-07 | Utilizacao de amidas do acido gama-hidroxibutirico no tratamento da toxicodependencia e particularmente do alcoolismo |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US6436998B1 (enExample) |
| EP (1) | EP0932597B1 (enExample) |
| JP (1) | JP4259615B2 (enExample) |
| AT (1) | ATE215065T1 (enExample) |
| AU (1) | AU4379097A (enExample) |
| CA (1) | CA2263328C (enExample) |
| DE (1) | DE69711411T2 (enExample) |
| DK (1) | DK0932597T3 (enExample) |
| ES (1) | ES2174287T3 (enExample) |
| HU (1) | HU228595B1 (enExample) |
| IT (1) | IT1283782B1 (enExample) |
| PT (1) | PT932597E (enExample) |
| WO (1) | WO1998006690A1 (enExample) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2355293C (en) * | 1998-12-23 | 2005-08-16 | Orphan Medical, Inc. | Microbiologically sound and stable solutions of gamma-hydroxybutyrate salt for the treatment of narcolepsy |
| FR2827859B1 (fr) | 2001-07-30 | 2005-09-23 | Lipha | Derives 4-(arylthio) - ou 4-(heteroarylthio) -butyrique dans la preparation de medicaments destines au traitement du diabete |
| WO2004041207A2 (en) * | 2002-11-01 | 2004-05-21 | Baylor Research Institute | Ghb treatment methods |
| US7838556B2 (en) * | 2006-02-21 | 2010-11-23 | University Of Maryland, Baltimore | Ethers of 3-hydroxyphenylacetic acid as selective gamma-hydroxybutyric acid receptor ligands |
| EP2062875A1 (en) * | 2007-11-13 | 2009-05-27 | LABORATORIO FARMACEUTICO C.T. S.r.l. | New polymorphic forms of n-[4-(trifluoromethyl)benzyl]-4-methoxybutyramide |
| US8778398B2 (en) * | 2008-11-04 | 2014-07-15 | Jazz Pharmaceuticals, Inc. | Immediate release formulations and dosage forms of gamma-hydroxybutyrate |
| US8771735B2 (en) * | 2008-11-04 | 2014-07-08 | Jazz Pharmaceuticals, Inc. | Immediate release dosage forms of sodium oxybate |
| CA2794171C (en) | 2010-03-24 | 2018-07-03 | Jazz Pharmaceuticals, Inc. | Controlled release dosage forms for high dose, water soluble and hygroscopic drug substances |
| US8591922B1 (en) | 2012-12-14 | 2013-11-26 | Jazz Pharmacuticals, Inc. | Gamma-hydroxybutyrate compositions and their use for the treatment of disorders |
| ITMI20132041A1 (it) * | 2013-12-06 | 2015-06-07 | Ct Lab Farm Srl | Derivati dell'acido gamma-idrossibutirrico, loro preparazione e loro uso medico. |
| US10398662B1 (en) | 2015-02-18 | 2019-09-03 | Jazz Pharma Ireland Limited | GHB formulation and method for its manufacture |
| ITUB20152860A1 (it) * | 2015-08-04 | 2017-02-04 | Laboratorio Farm C T S R L | Selezionata amide dell?acido ?-idrossibutirrico e suoi usi nel trattamento dell?abuso da alcool |
| ITUA20164040A1 (it) * | 2016-06-01 | 2017-12-01 | Laboratorio Farm C T S R L | Procedimento per la preparazione di polimorfo a |
| UY37341A (es) | 2016-07-22 | 2017-11-30 | Flamel Ireland Ltd | Formulaciones de gamma-hidroxibutirato de liberación modificada con farmacocinética mejorada |
| US12186296B1 (en) | 2016-07-22 | 2025-01-07 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US11602513B1 (en) | 2016-07-22 | 2023-03-14 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US11602512B1 (en) | 2016-07-22 | 2023-03-14 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US11504347B1 (en) | 2016-07-22 | 2022-11-22 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US11986451B1 (en) | 2016-07-22 | 2024-05-21 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US12478604B1 (en) | 2016-07-22 | 2025-11-25 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US20180263936A1 (en) | 2017-03-17 | 2018-09-20 | Jazz Pharmaceuticals Ireland Limited | Gamma-hydroxybutyrate compositions and their use for the treatment of disorders |
| CA3115122A1 (en) | 2018-11-19 | 2020-05-28 | Jazz Pharmaceuticals Ireland Limited | Alcohol-resistant drug formulations |
| EP3930702A1 (en) | 2019-03-01 | 2022-01-05 | Flamel Ireland Limited | Gamma-hydroxybutyrate compositions having improved pharmacokinetics in the fed state |
| TW202139986A (zh) | 2020-02-21 | 2021-11-01 | 愛爾蘭商爵士製藥愛爾蘭有限責任公司 | 治療原發性嗜睡症之方法 |
| WO2022076824A1 (en) | 2020-10-08 | 2022-04-14 | Jazz Pharmaceuticals Ireland Limited | Sodium oxybate to treat idiopathic hypersomnia |
| WO2023126076A1 (en) | 2022-01-03 | 2023-07-06 | Laboratorio Farmaceutico C.T. S.R.L. | Medical use of an amide of y-hydroxybutyric acid in the treatment of fragile x syndrome |
| US11583510B1 (en) | 2022-02-07 | 2023-02-21 | Flamel Ireland Limited | Methods of administering gamma hydroxybutyrate formulations after a high-fat meal |
| US11779557B1 (en) | 2022-02-07 | 2023-10-10 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| JP2026513019A (ja) | 2023-02-03 | 2026-04-22 | トリス・フアルマ・インコーポレーテツド | １晩１回の低ナトリウムオキシベート組成物 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3940258A (en) * | 1971-11-26 | 1976-02-24 | Gaf Corporation | Method for controlling aquatic weeds with N-phenylalkyl-γ-hydroxybutyramide |
| JPS6016432B2 (ja) * | 1977-07-26 | 1985-04-25 | グレラン製薬株式会社 | 複素環式化合物類およびその製造法 |
| DE3875361T2 (de) * | 1987-02-23 | 1993-03-25 | Ono Pharmaceutical Co | Thiazolidin-derivate. |
| IT1217783B (it) * | 1988-06-03 | 1990-03-30 | Farmaceutico Ct S R L Lab | Impiego di salo dell,acido gamma idrossi butirrico per la preparazione di composizioni farmaceutiche adatta ad essereimpiegate nella terapia dell,alcolismo e composizioni relative |
| IT1248588B (it) * | 1991-06-28 | 1995-01-19 | Gaetano Crepaldi | Composizioni farmaceutiche per la terapia dell'astinenza, del " craving", della dipendenza da sostanze stupefacenti, da sostanze psicoattive, da nicotina e dei disturbi alimentari. |
| AU2764495A (en) * | 1994-06-01 | 1995-12-21 | Arris Pharmaceutical Corporation | Compositions and methods for treating mast-cell mediated conditions |
| HUP9602538A3 (en) * | 1995-09-18 | 1997-08-28 | Sankyo Co | New urea and amide derivatives having acat inhibitory activity, their preparation and their use |
| ATE293603T1 (de) * | 1997-10-14 | 2005-05-15 | Mitsubishi Pharma Corp | Piperazin-verbindungen und ihre medizinische verwendung |
-
1996
- 1996-08-09 IT IT96MI001732A patent/IT1283782B1/it active IP Right Grant
-
1997
- 1997-08-07 AT AT97941921T patent/ATE215065T1/de active
- 1997-08-07 CA CA002263328A patent/CA2263328C/en not_active Expired - Lifetime
- 1997-08-07 DE DE69711411T patent/DE69711411T2/de not_active Expired - Lifetime
- 1997-08-07 WO PCT/EP1997/004309 patent/WO1998006690A1/en not_active Ceased
- 1997-08-07 PT PT97941921T patent/PT932597E/pt unknown
- 1997-08-07 HU HU9902437A patent/HU228595B1/hu unknown
- 1997-08-07 ES ES97941921T patent/ES2174287T3/es not_active Expired - Lifetime
- 1997-08-07 EP EP97941921A patent/EP0932597B1/en not_active Expired - Lifetime
- 1997-08-07 DK DK97941921T patent/DK0932597T3/da active
- 1997-08-07 AU AU43790/97A patent/AU4379097A/en not_active Abandoned
- 1997-08-07 JP JP50937298A patent/JP4259615B2/ja not_active Expired - Lifetime
- 1997-08-07 US US09/242,048 patent/US6436998B1/en not_active Expired - Lifetime
-
2001
- 2001-12-11 US US10/013,971 patent/US6770784B2/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| WO1998006690A1 (en) | 1998-02-19 |
| US20020165224A1 (en) | 2002-11-07 |
| JP4259615B2 (ja) | 2009-04-30 |
| EP0932597A1 (en) | 1999-08-04 |
| IT1283782B1 (it) | 1998-04-30 |
| ITMI961732A0 (enExample) | 1996-08-09 |
| DE69711411T2 (de) | 2002-11-07 |
| AU4379097A (en) | 1998-03-06 |
| HUP9902437A2 (hu) | 1999-12-28 |
| HUP9902437A3 (en) | 2001-07-30 |
| HU228595B1 (en) | 2013-04-29 |
| US6436998B1 (en) | 2002-08-20 |
| ATE215065T1 (de) | 2002-04-15 |
| CA2263328A1 (en) | 1998-02-19 |
| DK0932597T3 (da) | 2002-06-24 |
| ITMI961732A1 (it) | 1998-02-09 |
| EP0932597B1 (en) | 2002-03-27 |
| DE69711411D1 (de) | 2002-05-02 |
| JP2000516225A (ja) | 2000-12-05 |
| US6770784B2 (en) | 2004-08-03 |
| CA2263328C (en) | 2006-07-25 |
| ES2174287T3 (es) | 2002-11-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PT932597E (pt) | Utilizacao de amidas do acido gama-hidroxibutirico no tratamento da toxicodependencia e particularmente do alcoolismo | |
| AR007440A1 (es) | Compuestos triciclos fenilamino sustituidos y composiciones farmaceuticas de los mismos. | |
| ZA9710796B (en) | Oxyiminopregnanecarbolactones. | |
| HU9600963D0 (en) | Tricyclic amide and urea compounds useful for inhibition of g-protein function and for treatment of proliferative diseases | |
| ATE181551T1 (de) | Taxol-derivate | |
| AU1167199A (en) | Process for the preparation of acylated cyclic 1,3-dicarbonyl compounds | |
| MY104850A (en) | N-phenyloyrazole derivatives | |
| ES2008962A6 (es) | Proceso para la preparacion de nuevos compuestos de 2-guanidinotiazol | |
| MX9301361A (es) | Derivados de carbapenema antimicrobianos y su preparacion. | |
| GR1000156B (el) | ΜΕΘΟΔΟΣ ΠΑΡΑΣΚΕΥΗΣ ΝΕΩΝ ΠΑΡΑΓΩΓΩΝ ΤΡΙΚΥΚΛΙΚΩΝ ΑΜΙΝΩΝ ΤΗΣ ΤΕΤΡΑΥΔΡΟ-5,6,7,8ΝΑΦΘΟ[2,3b] ΔΙΥΔΡΟ-2,3 ΦΟΥΡΑΝΗΣ & ΤΗΣ ΤΕΤΡΑΥΔΡΟ-6,7,8,9 5Η-ΒΕΝΖΟΚΥΚΛΟΕΠΤΑ[2,3Β] ΔΙΥΔΡΟ-2,3 ΦΟΥΡΑΝΗΣ. | |
| BG103271A (en) | Derivatives of n-(benzothiazol-2-yl) piperidine-1-ethaneamines, method for their preparation and application as therapeutical means | |
| GR3023757T3 (en) | Cyclic benzylamino, benzylamido and benzylimido derivatives as antipsychotic agents. | |
| HUT70761A (en) | Alkyl derivatives of trazodone having action for central nervous system, pharmaceutical compositions for preparing thereof | |
| BG101671A (bg) | Диклавуланатна сол с диаминоетер и метод за получаването й | |
| FI860074A0 (fi) | Oktahydroindolizinfoereningar anvaendbara som smaertstillande medel. | |
| FI870460A0 (fi) | Foerfarande foer framstaellning av nya terapeutiskt anvaendbara 5-substituerade oktahydroindolizinderivat och vid foerfarandet anvaendbara mellanprodukter. | |
| TR200400907T4 (tr) | Beta D 5-Tiyoksiloz türevleri, bunları hazırlama yöntemi ve bunların terapötik kullanımları | |
| PL324884A1 (en) | Application of prostane derivatives and their compositions with antibiotics in treating bacterial infections | |
| FI934468A0 (fi) | Bensenborsyraderivat, foerfarande foer deras framstaellning och deras anvaendning som sytesmellanprodukter | |
| ATE283863T1 (de) | Verfahren zur herstellung von indolopyrrolocarbazol-derivaten | |
| ATE228359T1 (de) | Hemmung der leukotrienbiosynthese mittels harnstoffderivaten | |
| GB1410319A (en) | 6-aza-3h-1,4-benzodiazepines | |
| MX9703899A (es) | Derivado de arilacrilamida. | |
| NZ504104A (en) | Novel tricyclic compounds and their use in medicine, a process for their preparation, pharmaceutical compositions containing them, and their use in the manufacture of a medicament for treating diseases in which insulin is the underlying pathophysiological mechanism |